Bruker (NASDAQ:BRKR) Price Target Cut to $90.00

Bruker (NASDAQ:BRKR) had its price target decreased by Bank of America from $95.00 to $90.00 in a research note released on Monday, Benzinga reports. Bank of America currently has a buy rating on the medical research company’s stock.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. raised Bruker from a neutral rating to an overweight rating and lifted their target price for the stock from $60.00 to $90.00 in a research report on Wednesday, February 14th. Stifel Nicolaus lowered their price objective on Bruker from $81.00 to $77.00 and set a hold rating for the company in a report on Monday. The Goldman Sachs Group boosted their price objective on Bruker from $66.00 to $74.00 and gave the company a sell rating in a report on Wednesday, April 10th. Citigroup boosted their price objective on Bruker from $80.00 to $95.00 and gave the company a buy rating in a report on Wednesday, February 14th. Finally, UBS Group boosted their price objective on Bruker from $94.00 to $102.00 and gave the company a buy rating in a report on Friday, March 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $85.00.

Bruker Price Performance

BRKR stock opened at $76.70 on Monday. Bruker has a 52-week low of $53.79 and a 52-week high of $94.86. The stock has a market capitalization of $11.15 billion, a price-to-earnings ratio of 27.89, a price-to-earnings-growth ratio of 2.52 and a beta of 1.22. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95. The stock’s fifty day simple moving average is $83.53 and its 200-day simple moving average is $76.73.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The company had revenue of $721.70 million for the quarter, compared to analyst estimates of $729.88 million. During the same period last year, the company posted $0.64 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. Equities research analysts expect that Bruker will post 2.73 EPS for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 17th. Shareholders of record on Monday, June 3rd will be paid a $0.05 dividend. The ex-dividend date is Friday, May 31st. This represents a $0.20 dividend on an annualized basis and a yield of 0.26%. Bruker’s payout ratio is currently 7.27%.

Insider Transactions at Bruker

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $90.06, for a total value of $1,350,900.00. Following the completion of the sale, the director now directly owns 23,147 shares in the company, valued at $2,084,618.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 28.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BRKR. Sequoia Financial Advisors LLC acquired a new stake in Bruker during the 4th quarter valued at $2,384,000. Vaughan Nelson Investment Management L.P. grew its holdings in shares of Bruker by 62.5% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 315,210 shares of the medical research company’s stock valued at $23,161,000 after acquiring an additional 121,201 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Bruker by 79.4% during the 4th quarter. BNP Paribas Financial Markets now owns 188,201 shares of the medical research company’s stock valued at $13,829,000 after acquiring an additional 83,274 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Bruker by 55.7% during the 3rd quarter. Federated Hermes Inc. now owns 138,302 shares of the medical research company’s stock valued at $8,616,000 after acquiring an additional 49,487 shares in the last quarter. Finally, Buckhead Capital Management LLC purchased a new position in shares of Bruker during the 4th quarter valued at $1,634,000. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.